TERUMO CORPORATION

Financial Results for FYE/Mar.2008

April 30th, 2008





- I. Financial Results for FYE/Mar.2008
- II. Review of STeP UP (FY05-07)
- III. New mid-term business plan (FY08-10)



Financial Results for FYE/Mar.2008




Sales and profits enjoyed						
de	double-digit growth (Unit: billion)					
	FYE/Mar.2007	FYE/Mar.2008	Rate of change			
Net Sales	276.4	306.4	11%			
Gross Profit (%)	153.3(55.5%)	168.2(54.9%)	10%			
S.G.A Expenses (%)	94.9(34.3%)	101.3(33.1%)	7%			
Operating Income (%)	58.5(21.2%)	66.9(21.8%)	15%			
Ordinary Income (%)	58.0(21.0%)	64.2 (21.0%)	11%			
Net Income	37.2	43 .4	17%			
Average \$ exchange rate EUR	117 yen 150 yen	114 yen 2. 2% yen aj 162 yen 7. 7% yen d				




FYE/Mar.2008 Financial situation

(Unit: billion yen)




Net Sales (by Region)




J

Net Sales (by Product group)


(Unit: billion yen)




7




I. Review of STeP UP (FY05-07)









Achieved double-digit sales growth



Operating Income also achieved double-digit growth






Phoenix 2010

"Challenge for Dramatic Leap" Forget the past, create the new Terumo era.


Global-Innovation-Speed








Sales to reach 400 billion yen in FYE/Mar.2011




13

Operating income to reach 85 billion yen in FYE/Mar.2011




14




To become Terumo with a sense of presence in the world.

- 3 strategies
 - Reorganization of internal companies
 - Challenge toward innovation
 - Promote globalization








Mar.2007 Mar.2008 Mar.2009 Mar.2010 Mar.2011







Strategies of Cardiac & Vascular company


- Apply existing core technologies to new domains
- Continuous introduction of new products
- Increase production capacity for growth
- Aggressive expansion of business in emerging countries

Aiming to be No.3 in the global market










General Hospital company strategies

- Integration of Drugs and Devices
- Expansion of B2B business on a global level
- Enhancement and improvement of existing products for better safety

Aiming to be No.3 in the global market



 Blood Transfusion company strategies Business expansion in the two segments. 						
		<u>FY07</u>	<u>FY12</u>			
Whole blood	Market size	100 billion yen	130			
collection	Terumo share	16%	27			
Aphaeresis collection	Market size	90 billion yen	110			
	Terumo share	3%	10			
(TACSI) Automatic centrifugal separation system		(TACURA) New aphaeresis system				
22						



Blood Transfusion company strategies

Opportunities for further growth
Cell therapy and NRC (Neo Red Cell)



Aiming to be No.1 in the global market in the long-term



Consumer Healthcare company strategies

- Business with general consumers
- Brand image
- Preventive medical-care
- Marketing outside Japan



Capital investment of 70 billion yen (FY08-10) Expansion of production capacity centering on interventional products

Plants in Europe and America Increasing local production of catheters

<u>Vietnam Plant</u> Responding to increasing demand for medical equipment and interventional products Operation start: 1Q of 2008 <u>New Ashitaka factory</u> Responding to increasing demand for interventional products Construction start: September 2008 Operation start: Mid 2009 (planned) Target markets: Entire world



R&D 57 billion yen (FY08-10)

Clinical trials of new products


- •Nobori in Japan
- DuraHeart in Japan and the U.S.
- •Anaconda in the U.S.

Products under development

- •NRC, Nanocapsules
- Next-generation DES







FY08: Increasing sales and profits by reducing such negative impact of foreign exchange and NHI price revisions

(Unit: billion yen)

	FYE/Mar.08	FYE/Mar.09	Growth
Sales	306.4	318.0	4%
Operating Profit	66.9	68.0	2%
R&D expenses	15.8	18.0	14%
Capital Investment	15.7	24.0	53%






Reference



PTCA Balloon "Hiryu" is No.1 Share in Japan

Contributing to medical economic improvement
Supports a variety of needs with a single unit, completing treatment with a small number of catheters





Ultrasound diagnostic system in Japan

- High-resolution ultrasound diagnostic system with superior trackability toward the target lesion.
- •Expanding market due to DES problem. FYE/Mar. 11 Global 40 billion yen
- •Sales target FYE/Mar.09 : 3 billion yen \Rightarrow FYE/Mar.11 : 5
- Developing product OFDI




Catheter "ViewIT"

Monitor "VISIWAVE"






Growing Market : 300 billion




Blood Transfusion products


TACSI : Terumo Automated Centrifuge & Separator Integration








Bag



Collaboration with Andreas Hettich.

The automation of the blood component production eliminates the most sensitive manual steps in the blood component process. Often these steps affect the quality of the components produced and lead to possible product losses. Furthermore the automation not only reduces the manual operations, but considerably simplifies the processes and limit the equipments required for this process. It shall prove itself to be very cost-effective.





IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: CCD@terumo.co.jp

This document contains forward-looking statements that reflect management's current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.

